More than 55% of patients taking Elahere, an ovarian cancer approved in 2022, may experience vision loss, according to a new study.
The FDA's label for Elahere (mirvetuximab soravtansine) warns of potential corneal toxicity. This label prompted Stanford University researchers to conduct the first real-world study on the drug's ocular toxicity.
The study followed 18 women (36 eyes) who received mirvetuximab for about six months, according to an Oct. 17 news release from the American Academy of Ophthalmology.
Results showed that more than 55% of patients experienced decreased vision due to cornea damage, and 69% of eyes showed signs of corneal toxicity.
The drugmaker advises patients to see an eye care professional before beginning the treatment and to use eye drops before and during treatment. The study found that using strong topical corticosteroids and adjusting the dosage or spacing out treatments significantly improved symptoms.
Vision returned to normal in 65% of eyes and cornea toxicity significantly improved in almost all eyes.
The researchers will present these findings at the American Academy of Ophthalmology's annual meeting, offering guidance on optimizing care for affected patients.